Reveals ITGB2-AS1's role in promoting ovarian cancer growth, suggesting a new treatment target.
Long non-coding RNAs (lncRNAs) are involved in the development and progression of ovarian cancer (OC). Super-enhancers play vital roles in epigenomic regulation. We investigated the functions and mechanisms of the super-enhancer-driven OC-specific lncRNA ITGB2-AS1. In this study, we revealed that the lncRNA ITGB2-AS1 was abnormally expressed in OC tissues and cells and was associated with poor prognosis. In vitro , ITGB2-AS1 silencing attenuated the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of SKOV3 and A2780 cells, whereas ITGB2-AS1 overexpression showed the opposite effect. ITGB2-AS1 inhibition in SKOV3 cells reduced tumor growth and EMT progression in vivo . Further analysis revealed that the transcription factor TFAP2C acts on a specific super-enhancer and drives ITGB2-AS1 to activate transcription. `ITGB2-AS1 directly binds to IQGAP1 protein, positively regulates its expression, and activates the canonical Wnt/β-catenin signaling pathway. The TFAP2C / ITGB2-AS1 / IQGAP1 / β-catenin axis may be a potential target for OC treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: